JP2020520358A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520358A5
JP2020520358A5 JP2019563493A JP2019563493A JP2020520358A5 JP 2020520358 A5 JP2020520358 A5 JP 2020520358A5 JP 2019563493 A JP2019563493 A JP 2019563493A JP 2019563493 A JP2019563493 A JP 2019563493A JP 2020520358 A5 JP2020520358 A5 JP 2020520358A5
Authority
JP
Japan
Prior art keywords
pyrimidine
ethylamino
benzo
ethoxy
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563493A
Other languages
English (en)
Japanese (ja)
Other versions
JP7159215B2 (ja
JP2020520358A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/062844 external-priority patent/WO2018210988A1/en
Publication of JP2020520358A publication Critical patent/JP2020520358A/ja
Publication of JP2020520358A5 publication Critical patent/JP2020520358A5/ja
Application granted granted Critical
Publication of JP7159215B2 publication Critical patent/JP7159215B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563493A 2017-05-18 2018-05-17 Pge2レセプター調節剤としてのピリミジン誘導体 Expired - Fee Related JP7159215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017061989 2017-05-18
EPPCT/EP2017/061989 2017-05-18
PCT/EP2018/062844 WO2018210988A1 (en) 2017-05-18 2018-05-17 Pyrimidine derivatives as pge2 receptor modulators

Publications (3)

Publication Number Publication Date
JP2020520358A JP2020520358A (ja) 2020-07-09
JP2020520358A5 true JP2020520358A5 (enExample) 2021-07-26
JP7159215B2 JP7159215B2 (ja) 2022-10-24

Family

ID=62196584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563493A Expired - Fee Related JP7159215B2 (ja) 2017-05-18 2018-05-17 Pge2レセプター調節剤としてのピリミジン誘導体

Country Status (32)

Country Link
US (1) US11839613B2 (enExample)
EP (1) EP3625228B1 (enExample)
JP (1) JP7159215B2 (enExample)
KR (1) KR102626982B1 (enExample)
CN (1) CN110612299A (enExample)
AR (1) AR111808A1 (enExample)
AU (1) AU2018268311B2 (enExample)
BR (1) BR112019024105A2 (enExample)
CA (1) CA3060394A1 (enExample)
CL (1) CL2019003274A1 (enExample)
CO (1) CO2019010505A2 (enExample)
CR (1) CR20190560A (enExample)
CY (1) CY1124799T1 (enExample)
DK (1) DK3625228T3 (enExample)
EA (1) EA201992677A1 (enExample)
ES (1) ES2887041T3 (enExample)
HR (1) HRP20211380T1 (enExample)
HU (1) HUE056382T2 (enExample)
IL (1) IL270620B2 (enExample)
LT (1) LT3625228T (enExample)
MA (1) MA49128A (enExample)
MX (1) MX388257B (enExample)
PE (1) PE20191811A1 (enExample)
PH (1) PH12019502564A1 (enExample)
PL (1) PL3625228T3 (enExample)
PT (1) PT3625228T (enExample)
RS (1) RS62398B1 (enExample)
SG (1) SG11201908097YA (enExample)
SI (1) SI3625228T1 (enExample)
TW (1) TW201900178A (enExample)
UA (1) UA125124C2 (enExample)
WO (1) WO2018210988A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Agc株式会社 プロスタグランジンe2レセプターep2/ep4デュアルアンタゴニスト
JP2023539113A (ja) * 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
EP4359399A4 (en) 2021-06-24 2025-04-23 Reservoir Neuroscience, Inc. EP2 antagonist compounds
JP2024524986A (ja) 2021-06-24 2024-07-09 レザボア ニューロサイエンス,インコーポレイテッド Ep2アンタゴニスト化合物
CN113248354B (zh) * 2021-07-07 2022-04-22 山东国邦药业有限公司 一种氟氯苯乙酮的合成方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CN114539193B (zh) * 2022-01-20 2024-08-06 安徽普利药业有限公司 一种盐酸胺碘酮中间体的制备方法
CN116041245B (zh) * 2022-12-30 2025-03-07 上海毕得医药科技股份有限公司 一种4-(二氟甲氧基)-1h-吲哚-2-羧酸的制备方法
EP4648851A1 (en) 2023-01-10 2025-11-19 Astrazeneca AB Substituted (hetero)anilines and their use
WO2025149498A1 (en) 2024-01-09 2025-07-17 Astrazeneca Ab Benzylpiperidine derivatives as trp4 antagonists for the treatment of inflammatory diseases
TW202604507A (zh) 2024-05-02 2026-02-01 瑞士商愛杜西亞製藥有限公司 經n-取代之吲哚衍生物的結晶形式

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AU2000234451B2 (en) 2000-03-24 2005-09-29 Asterand Uk Acquisition Limited Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
JP2005532291A (ja) 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
MXPA04009961A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
CA2485485A1 (en) 2002-05-23 2003-12-04 Theratechnologies Inc. Antagonistic peptides of prostaglandin e2 receptor subtype ep4
CN100408570C (zh) 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
CN1871240B (zh) 2003-08-26 2012-11-07 帝人制药株式会社 吡咯并嘧啶酮衍生物
CA2536870C (en) 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
AU2005238291A1 (en) 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
KR20070006890A (ko) 2004-05-04 2007-01-11 화이자 인코포레이티드 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ep4受容体アンタゴニストとしてのインドールアミド誘導体
CA2654811A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
AU2007283404B2 (en) 2006-08-11 2013-04-18 Merck Canada Inc. Thiophenecarboxamide derivatives as EP4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
CA2679175C (en) 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
CN101636385B (zh) 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
KR20090122931A (ko) 2007-03-26 2009-12-01 아스테라스 세이야쿠 가부시키가이샤 오르니틴 유도체
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
EP2172447A4 (en) 2007-07-03 2011-08-24 Astellas Pharma Inc amide
AU2008309517B2 (en) 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
EP2254415B1 (en) 2008-02-19 2013-01-23 Janssen Pharmaceutica, N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
ES2518919T3 (es) 2008-05-14 2014-11-05 Astellas Pharma Inc. Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
CN102149384B (zh) 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CN102164942B (zh) 2008-09-19 2017-02-15 生物科技研究有限公司 三萜系化合物及其使用的方法
MX2011003166A (es) 2008-09-25 2011-04-27 Merck Frosst Canada Ltd Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4.
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
CN102711757A (zh) 2009-11-23 2012-10-03 莱西肯医药有限公司 用于治疗肠易激综合征的方法和分析法
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
WO2012039972A1 (en) 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition
ES2537017T3 (es) 2010-09-29 2015-06-01 Nb Health Laboratory Co. Ltd. Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
CA2816679A1 (en) 2010-11-17 2012-05-24 Novartis Ag 3-(aminoaryl)-pyridine compounds
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
WO2012149528A1 (en) 2011-04-29 2012-11-01 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
EP2721011B1 (en) 2011-06-20 2017-09-06 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
PL2729445T3 (pl) 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cykliczne pochodne aminowe jako antagoniści receptora EP4
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
PE20151412A1 (es) 2012-11-27 2015-10-10 Thomas Helledays Stiftelse For Medicinsk Forskning Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
BR112015030095B1 (pt) 2013-05-30 2023-02-28 Idorsia Pharmaceuticals Ltd Moduladores do receptor de cxcr7
CN105431416B (zh) 2013-06-12 2019-01-08 科研制药株式会社 4-炔基咪唑衍生物和含有其作为有效成分的药物
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
SI3057959T1 (en) 2013-10-17 2018-07-31 Vertex Pharmaceuticals Incorporated DNA-PK INHIBITORS
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
JP6200596B2 (ja) 2013-12-17 2017-09-20 イーライ リリー アンド カンパニー ジメチル安息香酸化合物
HUE035698T2 (en) 2013-12-17 2018-05-28 Lilly Co Eli Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ep4配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
WO2015167825A1 (en) 2014-04-29 2015-11-05 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
SG11201609770TA (en) 2014-05-23 2016-12-29 Eisai R&D Man Co Ltd Combination therapies for the treatment of cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
HUE052969T2 (hu) 2015-01-09 2021-05-28 Ono Pharmaceutical Co Triciklusos spiro vegyület
JP6689297B2 (ja) 2015-07-23 2020-04-28 武田薬品工業株式会社 複素環化合物
CA3002144C (en) 2015-10-16 2024-01-23 Eisai R&D Management Co., Ltd. Ep4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체

Similar Documents

Publication Publication Date Title
JP2020520354A5 (enExample)
JP2020520357A5 (enExample)
HRP20211380T1 (hr) Derivati pirimidina kao modulatori receptora pge2
EA009943B1 (ru) Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний
JP4638355B2 (ja) チアゾール誘導体
WO2021161230A4 (en) Small molecule sting antagonists
IL259424A (en) History of indole converted to nitrogen as pge2 receptor modulators
JP6619333B2 (ja) 複素環式誘導体およびその使用
JP2018534328A5 (enExample)
CA2905751A1 (en) Novel compounds and compositions for inhibition of fasn
RU2019132212A (ru) Селективные ингибиторы hdac6
BRPI0609892A2 (pt) composto ou um sal ou pró-droga do mesmo, composição farmacêutica, uso de um composto ou um sal ou pró-droga farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a apreparação de um composto
JP2004502768A (ja) 置換インドールオキソアセチックピペラジン誘導体の組成物と抗ウイルス活性
JP2020520356A5 (enExample)
JP2014520885A5 (enExample)
RU2019123319A (ru) Пиразолопиримидины и способы их применения
JP2013514308A5 (enExample)
KR20070113259A (ko) 티아디아졸 치환된 쿠마린 유도체 및 류코트리엔 생합성억제제로서의 이의 용도
RU2713937C2 (ru) Пиперидинилпиразолопиримидиноны и их применение
TW200306817A (en) Pharmaceutical composition for treating or preventing virus infectious diseases
JP2010509402A5 (enExample)
JP7604636B2 (ja) 新規なジアシルグリセリドo-アシルトランスフェラーゼ2阻害剤としてのベンゾイミダゾロン誘導体の製造
RU2466130C2 (ru) Бициклические гетероциклические соединения в качестве ингибиторов fgfr
AU2006299671A1 (en) Substituted quinolines as inhibitors of leukotriene biosynthesis
TW200418452A (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases